[Clinical results of UFT plus anticoagulants as a postoperative adjuvant in lung cancer patients].
Warfarin, Ticlopidine and UFT as postoperative adjuvant have been administered patients with stage III and IV lung cancer who underwent surgical resection. In a controlled trial, 55 patients were divided into two groups, one with anticoagulants and UFT (27 cases), the other with UFT alone (28 cases). The prognoses of the two groups were followed for 6 years. The anticoagulant group demonstrated a statistically greater interval from operation to recurrence the control group, although the recurrence rates and the interval from recurrence to death were almost the same between the two groups. Survival rates of anticoagulant group were always superior to those of control group after 12 months postoperatively, and the median survival was about twice that of the control group. Although survival rates between the two groups revealed no statistical difference, in patients with adenocarcinoma, the difference between the two groups was statistically significant.
D000925:Anticoagulants / Q000008:administration & dosage* / Q000494:pharmacology; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage* / Q000494:pharmacology; D004357:Drug Synergism; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000601:surgery; D011184:Postoperative Period; D011379:Prognosis; D011897:Random Allocation; D005641:Tegafur / Q000008:administration & dosage / Q000494:pharmacology; D014498:Uracil / Q000008:administration & dosage / Q000494:pharmacology
D000925:Anticoagulants; D005641:Tegafur; D014498:Uracil